Finland· FI-REL-REL44419

Pentiro

A levodopa, decarboxylasehemmer und comt-hemmer product containing levodopa + carbidopa monohydrate + entacapone, registered in Finland by STADA Arzneimittel AG. The same ATC class is registered in 12 of our 19 countries.

ATC N04BA03

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedPentiroATCN04BA03REGISTER NO.FI-REL-REL44419PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Levodopa, decarboxylasehemmer und comt-hemmer is registered in 12 of 19 countries.

Countries holding a registration under ATC N04BA03 (levodopa, decarboxylasehemmer und comt-hemmer), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 8 of them publish a price we can compare per daily dose

Levodopa, decarboxylasehemmer und comt-hemmer · ATC N04BA03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of levodopa, decarboxylasehemmer und comt-hemmer costs, country by country.

Normalised to the WHO defined daily dose (0.45 g), the median price runs from $1.36 in Italy to $5.49 in Switzerland — a ×4.0 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Levodopa, decarboxylasehemmer und comt-hemmer · price per daily dose (0.45 g)

USD · FX 28 Sept 2026

  • CH Switzerland$5.49
  • IT Italy$1.36
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Levodopa + Carbidopa monohydrate + Entacapone
Manufacturer
STADA Arzneimittel AG
Country
Finland (FI)
ATC code
N04BA03
ATC class
Levodopa, Decarboxylasehemmer und COMT-Hemmer
Defined daily dose
0.45 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

158 interactions on record for levodopa, decarboxylasehemmer und comt-hemmer.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Levodopa, decarboxylasehemmer und comt-hemmer · interactions on record

158 records

  • 4 severe
  • 122 moderate
  • 14 minor

Most severe, free to view

  • ProcarbazineL01XB01severe
  • OzanimodL04AA38severe
  • OzanimodL04AE02severe
  • Methylthioninium chlorideV03AB17severe

18 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Levodopa, decarboxylasehemmer und comt-hemmer in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All levodopa, decarboxylasehemmer und comt-hemmer products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Lecigimon, Trigelan
  • Belgium · Lecigen
  • Bulgaria · Лесигон
  • Czechia · Lecigimon, Trigelan
  • Germany · Lecigon, Levodopa/Carbidopa/Entacapon Abz
  • Denmark · Lecigon, Levodopa/Carbidopa/Entacapone G.L. Pharma
  • Estonia · Levodopa/Carbidopa/Entacapone Teva
  • Spain · Lecigon
  • France · Lecigimon, Levodopa/Carbidopa/Entacapone Teva
  • United Kingdom (Northern Ireland) · Lecigon
  • Greece · Levodopa+carbidopa+entacapone Mylan
  • Croatia · Lecigon
  • Hungary · Lecigon, Levodopa/Carbidopa/Entacapone Teva
  • Ireland · Lecigon
  • Italy · Lecigimon, Levodopa/Carbidopa/Entacapone Mylan
  • Luxembourg · Lecigimon
  • Latvia · Levodopa/Carbidopa/Entacapone Teva
  • Netherlands · Lecigon, Levodopa/Carbidopa/Entacapon G.L. Pharma
  • Norway · Lecigon
  • Poland · Lecigon
  • Portugal · Lecigon
  • Romania · Lecigon, Levodopa/Carbidopa/Entacaponă Teva
  • Sweden · Lecigon, Levodopa/Carbidopa/Entacapone Pharmexon
  • Slovenia · Lecigon
  • Slovakia · Lecigon, Trigelan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f47d43f3-1246-47b8-a08f-e4837970ba14
GET /v1/drugs/f47d43f3-1246-47b8-a08f-e4837970ba14?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.45",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "g",
  "strength": "175 mg / 43.75 mg / 200 mg",
  "atc_label": "levodopa, dekarboksylaasin estäjä ja COMT-estäjä",
  "ma_number": "31892",
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": null,
  "fimea_rel_id": "REL44419",
  "authorised_at": "2014-10-01"
}

See everything about levodopa, decarboxylasehemmer und comt-hemmer.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.